Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-valent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Hansenula Polymorpha)
- Development stage
- Unknown
- Lead developer
- Shanghai Bovax Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is a non-infectious recombinant quadrivalent vaccine designed to prevent Human Papillomavirus (HPV) infections. It is composed of highly purified virus-like particles (VLPs) derived from the L1 capsid proteins of HPV types 6, 11, 16, and 18. The vaccine is produced using *Hansenula polymorpha* as the expression system. Developed by Shanghai Bovax Biotechnology Co., Ltd. and Chongqing Bovax Biopharmaceutical, it aims to prevent cervical/vaginal precancerous lesions, cervical cancer, and genital warts associated with these specific HPV types.
- Other names
- 4-valent HPV VaccineQuadrivalent HPV recombinant vaccine4-valent hpv recombinant vaccine
Beyond the preview
Go deeper on 4-valent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Hansenula Polymorpha).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4-valent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Hansenula Polymorpha).